Efficacy and Safety of Combination of Brompheniramine and Phenylephrine for the Symptoms Relief of Rhinitis

Launched by ACHE LABORATORIOS FARMACEUTICOS S.A. · Jul 12, 2011

Keywords

ClinConnect Summary

This study evaluate the efficacy and safety of experimental drug The study was designed to evaluate the efficacy and safety of fixed combinations Decongex® Plus Syrup and Decongex® Plus Oral Solution (consisting of brompheniramine maleate and phenylephrine hydrochloride) compared to Resfenol® Oral Solution (paracetamol, maleate chlorpheniramine and phenylephrine hydrochloride) in the treatment of nasal congestion and rhinorrhea present in acute attacks of viral rhinitis (common cold) and allergic. This study population will consist in participants of both sexes, aged between 6 to 11 years o...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients between 2 and 12 years old, of both sexes. Must be responsible be able to understand and provide ICF and able to allow compliance to treatment and protocol requirements, fulfilling the regular visits;
• • 2. Patients with symptoms of acute inflammation upper airway, starting between 24 and 48 hours of their inclusion in this study protocol;
• • 3. Presence of runny nose classification moderate or severe (score 2 or 3), according the responsible evaluation;
• • 4. Presence of nasal congestion classification moderate or severe (score 2 or 3), according the responsible evaluation.
• Exclusion Criteria:
• • 1. Patients younger than 2 years or percentile for body weight and/or height less than 25;
• • 2. History of nasal obstruction in chronic rhinosinusitis and / or nasal polyposis;
• • 3. Oral chronic respirator with history for six months;
• • 4. Personal history of nasal surgery that in the opinion of the investigator can influence the resistance to nasal airflow;
• • 5. Patients who have a clinical history confirmed (diagnosed) with asthma;
• • 6. Patients under medicine treatment for chronic allergy;
• • 7. Patients with gastroesophageal reflux disease;
• • 8. Presence of psychiatric illness of any kind;
• • 9. Presence of mental retardation from any cause;
• • 10. Diagnosis of renal or hepatic failure;
• • 11. Patients with genetic syndromes;
• • 12. History of hypersensitivity to (s) drug (s) of study or their excipients;
• • 13. Use of prohibited medicine within the prescribed period before the V0 - Inclusion Visit (Table 1);
• • 14. Patients who participated in the last 12 months, of clinical trials protocols;
• • 15. Patients who didn´t updated vaccine book;
• • 16. Relatives of sponsor´s or study site´s employee;
• • 17. Suggestive signs of bacterial infection of upper airways at rhinoscopy, otoscopy or oroscopy;
• • 18. Presence of anemic/inflamed turbinate at anterior rhinoscopy;
• • 19. Presence of septal deviation grade II and III (in any region and any nasal cavity) and / or nasal polyps, or other conditions determinants of nasal obstruction;
• • 20. Presence of purulent or mucopurulent secretion, nasal vault or mal formations (cleft lip or cleft nasolabial corrected or not) in nasal vestibule;
• • 21. Current evidence of clinically significant diseases: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, autoimmune, pulmonary, or another disease that block the patient participation;
• • 22. Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the patient or interfere with the endpoints of study.